- Home
- AQB vs NXTS Comparison
AQB vs NXTS Comparison
Compare AQB & NXTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AQB | NXTS |
|---|---|---|
| Founded | 1991 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Agricultural Chemicals |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 5.3M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AQB | NXTS |
|---|---|---|
| Price | $1.53 | $1.94 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 485.9K | 56.1K |
| Earning Date | 05-14-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.66 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,472,659.00 | $263,445.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.70 | $0.55 |
| 52 Week High | $2.95 | $23.80 |
Technical Indicators
Market Signals| Indicator | AQB | NXTS |
|---|---|---|
| Relative Strength Index (RSI) | 77.43 | 40.56 |
| Support Level | $0.86 | $1.43 |
| Resistance Level | N/A | $2.16 |
| Average True Range (ATR) | 0.14 | 0.22 |
| MACD | 0.07 | 0.12 |
| Stochastic Oscillator | 86.85 | 65.75 |
Price Performance
Historical ComparisonAbout AQB AquaBounty Technologies Inc.
AquaBounty Technologies Inc is engaged in the field of land-based aquaculture and the use of technology to improve the productivity and sustainability. The company's objective is to ensure the availability of high-quality seafood to meet consumer demand while addressing critical production constraints in the popular farmed species.
About NXTS Nexentis Technologies Inc. Common Stock
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.